- CONDITION CENTERS
Bob Hoffman, Senior Vice President, Sales and Marketing, Generics Division
Lupin Pharmaceuticals, Inc. (LPI), a wholly owned subsidiary of Lupin Ltd., is among the top 4 pharmaceutical companies in India. With its US sales and marketing headquarters located in Baltimore, Maryland, LPI is dedicated to delivering affordable, high-quality generic medications.
Recognized as one of the top 10 fastest growing generic manufacturers for the 3rd year in succession, LPI’s prescribing rate has grown more than 51%. LPI’s generics business is ranked 5th in total generic prescriptions dispensed, according to IMS Health’s National Prescription Audit (March 2011).
“The US generic business is one of Lupin’s primary drivers of value creation,” said Bob Hoffman, Senior Vice President, Sales and Marketing, Generics Division. “Lupin continues to increase its market share for most of its marketed products through increased focus on execution, strong relationships with trade partners, and an efficient and responsive supply chain, all supported by a globally integrated team determined to explore better ways to create value.”
Of the 30 generic products marketed in the United States, 14 are market leaders in terms of market share. Lupin holds the top 3 positions in 27 of these 30 generic products, and its growth is driven equally by inline as well as new product introductions. “A very lucrative product pipeline, new product launches, deep customer relationships, and world-class intellectual property capabilities have been the key to the success of our US generics business,” said Hoffman. “As the fastest growing generic player in the United States, we believe that we have the required momentum in place to accelerate this growth further. The ceiling is far from reached as we are yet to realize the true value of one of the best generic pipelines in the US market.”
A Robust Pipeline
Lupin continues to invest in building up its robust pipeline of important new products. During the 2011 fiscal year, the company filed 21 Abbreviated New Drug Applications (ANDAs) with the FDA, including a record 9 that were firstto-file, and received 8 approvals. The cumulative number of ANDA filings made by Lupin now stands at 148, with 48 approvals received to date. Of these, 77 Paragraph IV filings have been made and the cumulative first-to-file opportunities for the US generics market now stands at 20. Lupin continues to maintain its position as one of the top 10 ANDA filers for the US market.
Over the last few years, LPI has made significant investments to expand its product offerings in the United States through strategic partnerships. One major internal initiative is its imminent entry into the oral contraceptive market. Further, LPI continues to seek business development opportunities that are aligned with its strategic vision.
Lupin’s success rests on its efficient vertically integrated business model. With consistent and continued investments in augmented manufacturing capacities, its capabilities are completely attuned to its growth aspirations. State-of-theart manufacturing plants support the delivery of quality and scale. Integration of capabilities and capacities ensures delivery of a wide product portfolio catering to the needs of diverse markets. Lupin’s manufacturing teams strive to ensure that global standards of best manufacturing practices are implemented at every Lupin facility. Lupin’s goal is to deliver the best products all the time, every time. Our customers can depend on Lupin’s vigilant compliance and assured quality for their patients’ peace of mind.
Our reliability creates peace of mind. PT
For more information, please visit www.lupinpharmaceuticals.com or call 866.587.4617.
Lupin Now Offers Full Line of Generic Lotrel®
Lotrel® is a registered trademark of Novartis Corporation